News: Clinical Cancer Research

New Drug Mutes More Melanomas

Thursday, April 26th, 2012

Therapies targeted to a specific mutation in the BRAF gene can significantly reduce tumor burden in metastatic melanoma. But these therapies are not suitable for melanomas lacking the mutation, and even tumors carrying the BRAF mutation eventually become resistant to those therapies. Using human melanoma tumors implanted into mice, Ann Richmond, Ph.D., and colleagues assessed […]

Factor Sensitizes Cancer to Radiation

Friday, March 30th, 2012

Head and neck cancers have repeatedly been linked to infection with human papillomavirus (HPV), with more than half of oropharyngeal squamous cell carcinomas (HNSCCs) positive for HPV. Interestingly, HPV-positive HNSCCs respond better to radiation therapy and have a better prognosis than HPV-negative tumors. But the molecular pathways responsible for their different sensitivities are unclear. In […]